Related content

Combination therapy using oral S-1 and targeted agents against human tumor xenografts in nude mice

By                    

Experimental and Therapeutic Medicine, Vol. 3, Iss. 5, 2012-01 ,pp. : 755-762

Spandidos Publications

Access to resources Recommend Favorite

Prolonged survival of a patient with lung cancer after treatment with S-1, a new oral fluoropyrimidine anticancer drug

By Urata Yoshiko   Negoro Shunichi   Satouchi Miyako   Kurata Takayasu   Yoshimura Sho   Shimada Temiko   Takada Yoshiki  

Medical Oncology, Vol. 24, Iss. 1, 2007-01 ,pp. : 103-107

Humana Press, Inc

Access to resources Recommend Favorite

Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study

By Togawa Akira   Yoshitomi Hideyuki   Ito Hiroshi   Kimura Fumio   Shimizu Hiroaki   Ohtsuka Masayuki   Yoshidome Hiroyuki   Kato Atsushi   Sawada Shigeaki   Miyazaki Masaru  

International Journal of Clinical Oncology, Vol. 12, Iss. 4, 2007-08 ,pp. : 268-273

Springer Publishing Company

Access to resources Recommend Favorite

Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice

By Xiao Yong-Sheng   Tang Zhao-You   Fan Jia   Zhou Jian   Wu Zhi-Quan   Sun Qi-Man   Xue Qiong   Zhao Yan   Liu Yin-Kun   Ye Sheng-Long  

Journal of Cancer Research and Clinical Oncology, Vol. 130, Iss. 9, 2004-09 ,pp. : 546-550

Springer Publishing Company

Access to resources Recommend Favorite

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients

By Sakata Y.   Ohtsu A.   Horikoshi N.   Sugimachi K.   Mitachi Y.   Taguchi T.  

European Journal of Cancer, Vol. 34, Iss. 11, 1998-10 ,pp. : 1715-1720

Elsevier

Access to resources Recommend Favorite